- Conditions
- Neoplasms
- Interventions
- GSK3901961, GSK3845097, GSK4427296, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 3,021
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
- Interventions
- SC291
- Biological
- Lead sponsor
- Sana Biotechnology
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- Concord, California • Los Angeles, California • St. Helena, California + 14 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- SB-728mR-T, Cyclophosphamide
- Genetic · Drug
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • Norwalk, Connecticut • Orlando, Florida + 2 more
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer
- Interventions
- Fludarabine, Cyclophosphamide, E6 TCR, Aldesleukin
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed or Refractory Large B-cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
- Interventions
- 5-Azacytidine, Fludarabine, Melphalan, Alemtuzumab, Total Body Irradiation
- Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
- Interventions
- KITE-363, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Duarte, California • Stanford, California • Tampa, Florida + 1 more
- Conditions
- Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Interventions
- Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
- Drug · Procedure
- Lead sponsor
- Jennifer Crombie, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- SDX-105
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee • Houston, Texas
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Downey, California • Duarte, California + 90 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
- Biological · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 49
- States / cities
- Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
- Interventions
- TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2014
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Myeloma, Stem Cell Transplantation
- Interventions
- Lenalidomide, Melphalan, Stem Cell Infusion
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, fludarabine phosphate
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 215
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 140 more
- Conditions
- Liver Cancer
- Interventions
- GAP T cells, Cytoxan, Fludara
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2037
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- AL Amyloidosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
- Procedure · Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 117
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission
- Interventions
- imatinib mesylate, methotrexate, vincristine sulfate, leucovorin calcium, peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, allogeneic hematopoietic stem cell transplantation, total-body irradiation, tacrolimus, filgrastim, etoposide, cyclophosphamide, cytarabine, laboratory biomarker analysis
- Drug · Procedure · Radiation + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 97
- States / cities
- Atlanta, Georgia • Bloomington, Illinois • Canton, Illinois + 63 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess Blasts, Refractory Anemia, De Novo Myelodysplastic Syndrome, Childhood Myelodysplastic Syndrome
- Interventions
- filgrastim, busulfan, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
- Interventions
- Eribulin, Cyclophosphamide
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California